Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update
08 Mayo 2023 - 3:05PM
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a
commercial-stage biopharmaceutical company primarily focused on
developing and commercializing products in various therapeutic
areas, including opioid overdose, allergy, respiratory and
inflammatory disease, today announced that it will host an investor
conference call on Monday, May 15, 2023 at 2:00 p.m. Pacific Time
to discuss its financial and operating results for the first
quarter 2023 as well as provide a corporate update, which may
include an update concerning the results of the company’s special
meeting of stockholders scheduled to be held on May 15, 2023 at
10:00 a.m. Pacific Time as well as the proposals to be considered
and acted upon at the meeting. The company’s first quarter 2023
financial results news release is expected to be available after
1:00 p.m. Pacific Time on May 15, 2023, and on its website.
Event: Adamis Pharmaceuticals First Quarter 2023 Financial
Results Conference CallDate: Monday, May 15, 2023Time: 2 p.m. PT (5
p.m. ET)U.S. Dial-in (Toll Free): 1-877-423-9813Toll/International
Dial-in: 1-201-689-8573
David J. Marguglio, President and CEO of Adamis, will host the
call along with other members of the management team. The call is
open to the public and will provide an update on recent
developments, events that have taken place during the year, and
certain goals for future periods, and may also include an update
concerning the results of the company’s special meeting of
stockholders scheduled to be held on May 15, 2023 at 10:00 a.m.
Pacific Time as well as the proposals to be considered and acted
upon at the meeting. Forward-looking statements concerning
expectations regarding future company performance may be made
during the conference call.
A live audio webcast of the conference call will also be
available via this link, with a replay available shortly after the
live event.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty
biopharmaceutical company primarily focused on developing and
commercializing products in various therapeutic areas, including
opioid overdose, allergy, respiratory and inflammatory disease.
Company products approved by the FDA include ZIMHI® (naloxone)
Injection for the treatment of opioid overdose and
SYMJEPI® (epinephrine) Injection for use in the emergency
treatment of acute allergic reactions, including anaphylaxis. For
additional information about Adamis Pharmaceuticals, please
visit our website and follow us
on Twitter and LinkedIn.
Contact:
Adamis Investor Relations Robert UhlManaging DirectorICR
Westwicke 619.228.5886robert.uhl@westwicke.com
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfica de Acción Histórica
De May 2023 a May 2024